Indications for a ceftriaxone dosing regimen in Japanese paediatric patients using population pharmacokinetic/pharmacodynamic analysis and simulation

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 1, 2011, Pages 65-72

  Iida, Satofumi ^a   Kawanishi, Takehiko ^a   Hayashi, Masahiro ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

ceftriaxone; Japanese paediatric patients; pharmacodynamics; population pharmacokinetics

Indexed keywords

CEFTRIAXONE;

ADOLESCENT; ARTICLE; CHILD; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; JAPANESE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEISSERIA GONORRHOEAE; PRESCHOOL CHILD; RANDOM ERROR; SCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BODY WEIGHT; CEFTRIAXONE; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; INFANT, NEWBORN; JAPAN; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; TIME FACTORS;

EID: 78650407104     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01179.x     Document Type: Article

References (24)

1. Wise R, et al. Ro 13-9904: a cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study. J Antimicrob Chemother 1980; 6: 595-600.
2. Craig WA,. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
3. Doern GV, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45: 1721-1729.
4. Matsuzaki K, et al. [Antibacterial activity of ceftriaxone against various clinical strains isolated in 2004. Jpn J Antibiot 2005; 58: 283-289 [in Japanese].
5. McNamara PJ, et al. Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam. Biochem Pharmacol 1990; 40: 1247-1253.
6. Nerli B, et al. Structural specificity requirements in the binding of beta lactam antibiotics to human serum albumin. Chem Biol Interact 1997; 104: 179-202.
7. Nagamatsu I, et al. [Ceftriaxone therapy for pediatric infections. Jpn J Antibiot 1984; 37: 2003-2011 [in Japanese].
8. Satoh Y, et al. [Fundamental and clinical evaluation of ceftriaxone in the field of pediatrics. Jpn J Antibiot 1984; 37: 2034-2048 [in Japanese].
9. Meguro H, et al. [Clinical and pharmacokinetic study of ceftriaxone in pediatric bacterial infections. Jpn J Antibiot 1984; 37: 2049-2059 [in Japanese].
10. Toyonaga Y, et al. [Fundamental and clinical evaluation on ceftriaxone in the pediatric field. Jpn J Antibiot 1984; 37: 2060-2082 [in Japanese]. (Pubitemid 15189350)
11. Nakazawa S, et al. [Evaluation on ceftriaxone in the pediatric field. Jpn J Antibiot 1984; 37: 2083-2101 [in Japanese].
12. Motohiro T, et al. [Fundamental and clinical evaluation of ceftriaxone in the pediatric field. Jpn J Antibiot 1984; 37: 2152-2168 [in Japanese]. (Pubitemid 15189356)
13. Fujita K, et al. [Clinical and pharmacokinetic evaluation of ceftriaxone in children. Jpn J Antibiot 1984; 37: 2271-2282 [in Japanese]. (Pubitemid 15162770)
14. Minamitani M, et al. [Clinical evaluation of ceftriaxone in the pediatric field. Jpn J Antibiot 1984; 37: 2283-2297 [in Japanese].
15. Oshima J, et al. [Bioassay method for ceftriaxone (Ro 13-9904) concentration in body fluids. Chemotherapy (Tokyo) 1984; 32: 170-177 [in Japanese].
16. Anderson BJ, Holford NH,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332.
17. Holford NH,. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-332.
18. Tod M, et al. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47: 231-243.
19. Parke J, et al. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999; 59: 19-29.
20. Schaad UB, Stoeckel K,. Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrob Agents Chemother 1982; 21: 248-253. (Pubitemid 12112798)
21. Seng KY, et al. Retrospective population pharmacokinetic/pharmacodynamic analysis of pyridostigmine, a cholinesterase inhibitor, in Chinese males. J Pharm Pharmacol 2009; 61: 1187-1196.
22. Iida S, et al. The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults. Eur J Drug Metab Pharmacokinet 2009; 34: 107-115.
23. Patel IH, et al. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother 1981; 20: 634-641.
24. Patel IH, et al. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 1984; 25: 438-442.